Bispecific Antibodies in the Treatment of Hematologic Malignancies

被引：51

作者：

Duell, Johannes ^{[1
]}

Lammers, Philip E. ^{[2
]}

Djuretic, Ivana ^{[3
]}

Chunyk, Allison G. ^{[4
]}

Alekar, Shilpa ^{[4
]}

Jacobs, Ira ^{[5
]}

Gill, Saar ^{[6
,7
]}

机构：

[1] Univ Klinikum Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Baptist Canc Ctr, Memphis, TN USA

[3] Pfizer Inc, San Francisco, CA USA

[4] Pfizer Inc, La Jolla, CA USA

[5] Pfizer Inc, New York, NY 10017 USA

[6] Univ Penn, Blood & Marrow Transplantat Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 106卷 / 04期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; CAR T-CELLS; CLINICAL DEVELOPMENT; BLINATUMOMAB; THERAPY; RESISTANCE; DEPLETION; EFFICACY; SAFETY;

D O I：

10.1002/cpt.1396

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.

引用

页码：781 / 791

页数：11

共 50 条

[21] CLADRIBINE FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
BALTZ, JK
MONTELLO, MJ
CLINICAL PHARMACY, 1993, 12 (11): : 805 - 813
[22] Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian, Zheng
Liu, Ming
Zhang, Ya
Wang, Xin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[23] Redirecting T cells to hematological malignancies with bispecific antibodies
Velasquez, Mireya Paulina
Bonifant, Challice L.
Gottschalk, Stephen
BLOOD, 2018, 131 (01) : 30 - 38
[24] The state of the art of bispecific antibodies for treating human malignancies
Wang, Shuhang
Chen, Kun
Lei, Qi
Ma, Peiwen
Yuan, Andy Qingan
Zhao, Yong
Jiang, Youwei
Fang, Hong
Xing, Shujun
Fang, Yuan
Jiang, Ning
Miao, Huilei
Zhang, Minghui
Sun, Shujun
Yu, Zicheng
Tao, Wei
Zhu, Qi
Nie, Yingjie
Li, Ning
EMBO MOLECULAR MEDICINE, 2021, 13 (09)
[25] Bispecific antibodies for the treatment of neuroblastoma
Espinosa-Cotton, Madelyn
Cheung, Nai-Kong, V
PHARMACOLOGY & THERAPEUTICS, 2022, 237
[26] Bispecific antibodies for the treatment of hemophilia A
Shima, Midori
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (08) : 1029 - 1042
[27] Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs
Foster, Laahn H.
Lum, Lawrence G.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (07) : 707 - 720
[28] Monoclonal antibodies in hematologic malignancies: Clinical status - Introduction
Cheson, BD
ONCOLOGY-NEW YORK, 2001, 15 (03): : 9 - 9
[29] Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies
Al Hadidi, Samer
Heslop, Helen E.
Brenner, Malcolm K.
Suzuki, Masataka
MOLECULAR THERAPY, 2024, 32 (08) : 2444 - 2460
[30] Differentiation induction as a treatment for hematologic malignancies
Wilson H Miller Jr
Samuel Waxman
Oncogene, 2002, 21 : 3496 - 3506

← 1 2 3 4 5 →